DOCSLIB.ORG

MAPKAPK5 (Non Activated) Recombinant Human

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MAPKAPK5 (Non Activated) Recombinant Human Certificate of Analysis ProQinase™ MAPKAPK5 (non activated) mitogen-activated protein kinase-activated protein kinase 5 Recombinant Proteins Recombinant Recombinant Human Protein Kinase MAPKAPK5 Lot 001: Western blot analysis MAPKAPK5 HGNC Symbol: anti-MAPKAPK5 anti-GST Synonyms: PRAK kDa kDa 250 250 150 150 Product No.: 0380-0000-1 100 100 GST- GST- 75 75 Lot: 001 MAPKAPK5 MAPKAPK5 50 50 Description: Human MAPKAPK5 Amino acids M1-Q473 (as in NCBI/Protein entry 37 37 NP_620777.1)*, N-terminally fused to GST- 25 25 HIS6-Thrombin cleavage site 20 20 15 15 Product identity: MAPKAPK5, Lot 001, was confirmed as MAPKAPK5 by specific Western 500 ng GST-MAPKAPK5 500 ng GST-MAPKAPK5 Blotting using anti MAPKAPK5 antibody Kinase activity MAPKAPK5 (not activated) vs Theoretical MWFusion Protein: 84,116 Da active MAPKAPK5: 20000 Expression: Baculovirus infected Sf9 cells n = 3 Substrate (µg/well): : + Enzyme 1: no substrate : - Enzyme 2: 1 Purification: One-step affinity purification using 15000 3: 2 4: 4 GSH-agarose 10000 Storage buffer: 50 mM Tris-HCl, pH 8.0; 100 mM NaCl, 5 mM DTT, 4 mM reduced 5000 glutathione, 20% glycerol (cpm) activity Kinase 0 1 2 3 4 1 2 3 4 1 2 3 4 Storage temperature: -80°C 25 50 100 Avoid repeated freeze-thaw cycles! Kinase (ng/well) Protein concentration: 0.113 µg/µl (Bradford method using BSA [Sigma, cat# 20000 Substrate (µg/well): : + Enzyme n = 3 1: no substrate : - Enzyme A-7638, Lot 79H7641] as standard protein) 2: 1 15000 3: 2 4: 4 Coomassie stain: 10000 kDa 5000 250 (cpm) activity Kinase 150 0 1 2 3 4 1 2 3 4 1 2 3 4 25 50 100 100 GST- 75 MAPKAPK5 Kinase (ng/well) Final assay concentrations: - 60 mM HEPES-NaOH, pH 7.5 50 - 3 mM MgCl2 37 - 3 mM MnCl2 - 3 µM Na-orthovanadate - 1.2 mM DTT 25 - 50 µg / ml PEG 20 20.000 - 1 µM ATP (798,000 cpm 33P-γ-ATP) 15 - Substrate (variable): ATF2 - Recombinant MAPKAPK5 (not activated) or active 2.0 µg GST-MAPKAPK5 MAPKAPK5 (variable) Assay: 33PanQinase® Assay This product was manufactured at Reaction Biology in Freiburg, Germany, and is for in vitro research use only, not for use in humans or animals. © European Union, 2020. Material may not be reproduced or distributed without written permission from Reaction Biology Europe GmbH Reaction Biology www.reactionbiology.com [email protected] Certificate of Analysis - Page 2 - ProQinase™ MAPKAPK5 Recombinant Proteins Recombinant Product No.: 0380-0000-1 MAPKAPK5 Recombinant Fusion Protein Amino Acid Sequence 1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID 60 61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV 120 121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK 180 181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD PMGHHHHHHG RRRASVAAGI 240 241 LVPRGSPGLD GIYARGIQAS MSEESDMDKA IKETSILEEY SINWTQKLGA GISGPVRVCV 300 301 KKSTQERFAL KILLDRPKAR NEVRLHMMCA THPNIVQIIE VFANSVQFPH ESSPRARLLI 360 361 VMEMMEGGEL FHRISQHRHF TEKQASQVTK QIALALRHCH LLNIAHRDLK PENLLFKDNS 420 421 LDAPVKLCDF GFAKIDQGDL MTPQFTPYYV APQVLEAQRR HQKEKSGIIP TSPTPYTYNK 480 481 SCDLWSLGVI IYVMLCGYPP FYSKHHSRTI PKDMRRKIMT GSFEFPEEEW SQISEMAKDV 540 541 VRKLLKVKPE ERLTIEGVLD HPWLNSTEAL DNVLPSAQLM MDKAVVAGIQ QAHAEQLANM 600 601 RIQDLKVSLK PLHSVNNPIL RKRKLLGTKP KDSVYIHDHE NGAEDSNVAL EKLRDVIAQC 660 661 ILPQAGKGEN EDEKLNEVMQ EAWKYNRECK LLRDTLQSFS WNGRGFTDKV DRLKLAEIVK 720 721 QVIEEQTTSH ESQ 780 1-218: GST Red: HIS6-tag Pink: Thrombin blue: MAPKAPK5 MAPKAPK5 wt1 amino acid sequence 1 MSEESDMDKA IKETSILEEY SINWTQKLGA GISGPVRVCV KKSTQERFAL KILLDRPKAR 60 61 NEVRLHMMCA THPNIVQIIE VFANSVQFPH ESSPRARLLI VMEMMEGGEL FHRISQHRHF 120 121 TEKQASQVTK QIALALRHCH LLNIAHRDLK PENLLFKDNS LDAPVKLCDF GFAKIDQGDL 180 181 MTPQFTPYYV APQVLEAQRR HQKEKSGIIP TSPTPYTYNK SCDLWSLGVI IYVMLCGYPP 240 241 FYSKHHSRTI PKDMRRKIMT GSFEFPEEEW SQISEMAKDV VRKLLKVKPE ERLTIEGVLD 300 301 HPWLNSTEAL DNVLPSAQLM MDKAVVAGIQ QAHAEQLANM RIQDLKVSLK PLHSVNNPIL 360 361 RKRKLLGTKP KDSVYIHDHE NGAEDSNVAL EKLRDVIAQC ILPQAGKGEN EDEKLNEVMQ 420 421 EAWKYNRECK LLRDTLQSFS WNGRGFTDKV DRLKLAEIVK QVIEEQTTSH ESQ 480 blue: MAPKAPK5 sequence expressed in fusionprotein 1NCBI/Protein accession number NP_620777.1 This product was manufactured at Reaction Biology in Freiburg, Germany, and is for in vitro research use only, not for use in humans or animals. © European Union, 2020. Material may not be reproduced or distributed without written permission from Reaction Biology Europe GmbH Reaction Biology www.reactionbiology.com [email protected].
Load more

Recommended publications
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • Supporting Information Supporting Information Corrected July 15 , 2014 Yi Et Al
    Supporting Information Supporting Information Corrected July 15 , 2014 Yi et al. 10.1073/pnas.1404943111 SI Materials and Methods which no charge state could be determined were excluded MS/ Tumorsphere Growth Assay. Single-cell tumorsphere growth assays MS selection). Three independent experiments were performed. of human mammary epithelial (HMLER) (CD44high/CD24low)SA and HMLER (CD44high/CD24low)FA population cells were per- Phosphorylation Site Localization. The probability of correct phos- formed with ultra-low attachment surface six-well plates (Corn- phorylation site localization for each phosphorylation site was ing) and the mammary epithelial cell basal medium (MEBM) measured using an Ascore algorithm (1). This algorithm con- medium (Lonza) was supplemented with B27 (Invitrogen), 20 ng/mL siders all phosphoforms of a peptide and uses the presence or EGF, and 20 ng/mL basic FGF (BD Biosciences), and 4 μg/mL absence of experimental fragment ions unique to each to create an ambiguity score (Ascore). Parameters included a window size of heparin (Sigma). Single cells were cultured for 8 d and images were ± taken with a Nikon camera. 100 m/z units and a fragment ion tolerance of 0.6 m/z units. Sites with an Ascore of ≥13 (P ≤ 0.05) were considered to be ≥ ≤ Soft Agar Colony Growth Assay. Single-cell soft agar colony for- confidently localized, and those with an Ascore of 19 (P 0.01) mation and growth assays were performed to identify the tumor- were considered to be localized with near certainty. More than ≥ igenesis capacity of HMLER (CD44high/CD24low)SA and HMLER a 2.5-fold ratio ( 60.02%) was considered as a significant (CD44high/CD24low)FA population cells in vitro.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ～ClariCELL™ ～ Targets P.18 Detection of Protein-Protein Interactions ～ProbeX™～ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ～Premium～ P.20-21 FastLane™ Structures ～Standard～ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1～3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]
  • PRAK (MAPKAPK5) Antibody (T182) Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # Ap7216a
    9765 Clairemont Mesa Blvd, Suite C San Diego, CA 92124 Tel: 858.875.1900 Fax: 858.622.0609 PRAK (MAPKAPK5) Antibody (T182) Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP7216a Specification PRAK (MAPKAPK5) Antibody (T182) - Product Information Application WB,E Primary Accession Q8IW41 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Clone Names RB13233 Calculated MW 54220 Antigen Region 160-189 PRAK (MAPKAPK5) Antibody (T182) - Additional Information Gene ID 8550 Other Names MAP kinase-activated protein kinase 5, Western blot analysis of MAPKAPK5 Antibody MAPK-activated protein kinase 5, MAPKAP (T182) (Cat.#AP7216a) in Hela cell line lysates kinase 5, MAPKAP-K5, MAPKAPK-5, MK-5, (35ug/lane). MAPKAPK5 (arrow) was detected MK5, p38-regulated/activated protein kinase, using the purified Pab. PRAK, MAPKAPK5, PRAK Target/Specificity This PRAK(MAPKAPK5) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 160-189 amino acids from human PRAK(MAPKAPK5). Dilution WB~~1:1000 Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. Storage Maintain refrigerated at 2-8°C for up to 6 Western blot analysis of MAPKAPK5 (arrow) months. For long term storage store at -20°C using rabbit polyclonal MAPKAPK5 Antibody in small aliquots to prevent freeze-thaw (T182) (Cat.#AP7216a). 293 cell lysates (2 cycles. ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the Precautions MAPKAPK5 gene. PRAK (MAPKAPK5) Antibody (T182) is for research use only and not for use in diagnostic or therapeutic procedures.
    [Show full text]
  • Inhibitors of MBNL1-CUG RNA Binding with Distinct Cellular Effects Jason W
    Published online 20 April 2014 Nucleic Acids Research, 2014, Vol. 42, No. 10 6591–6602 doi: 10.1093/nar/gku275 Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects Jason W. Hoskins1, Leslie O. Ofori2, Catherine Z. Chen3,AmitKumar4, Krzysztof Sobczak1, Masayuki Nakamori1, Noel Southall3, Samarjit Patnaik3, Juan J. Marugan3, Wei Zheng3, Christopher P. Austin3, Matthew D. Disney4, Benjamin L. Miller5 and Charles A. Thornton1,* 1Department of Neurology, University of Rochester, Rochester, NY 14642, USA, 2Department of Chemistry, University of Rochester, Rochester, NY 14642, USA, 3Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA, 4Department of Chemistry, Scripps Florida, Jupiter, FL 33458, USA and 5Department of Dermatology, University of Rochester, Rochester, NY 14642, USA Received May 8, 2013; Revised March 21, 2014; Accepted March 24, 2014 ABSTRACT INTRODUCTION Myotonic dystrophy type 1 (DM1) is a dominantly Myotonic dystrophy type 1 (DM1) is the prototypical ge- inherited neuromuscular disorder resulting from ex- netic disease resulting from a toxic gain-of-function by mu- pression of RNA containing an expanded CUG repeat tant RNA (1). RNA toxicity has been implicated in several (CUGexp). The pathogenic RNA is retained in nuclear other disorders that share a distinctive set of genetic fea- foci. Poly-(CUG) binding proteins in the Muscleblind- tures: the causal mutations are large polymorphic expan- sions of simple tandem repeats that are genetically unsta- like (MBNL) family are sequestered in foci, caus- ble and located in non-coding regions of the genome (2–9). ing misregulated alternative splicing of specific pre- The underlying disease mechanisms are heterogeneous and exp mRNAs.
    [Show full text]
  • Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
    Supplementary Online Content Chen G, McQuade JL, Panka DJ, et al. Clinical, molecular and immune analysis of dabrafenib-trametinib combination treatment for metastatic melanoma that progressed during BRAF inhibitor monotherapy: a phase 2 clinical trial. JAMA Oncology. Published online April 28, 2016. doi:10.1001/jamaoncol.2016.0509. eMethods. eReferences. eTable 1. Clinical efficacy eTable 2. Adverse events eTable 3. Correlation of baseline patient characteristics with treatment outcomes eTable 4. Patient responses and baseline IHC results eFigure 1. Kaplan-Meier analysis of overall survival eFigure 2. Correlation between IHC and RNAseq results eFigure 3. pPRAS40 expression and PFS eFigure 4. Baseline and treatment-induced changes in immune infiltrates eFigure 5. PD-L1 expression eTable 5. Nonsynonymous mutations detected by WES in baseline tumors This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 eMethods Whole exome sequencing Whole exome capture libraries for both tumor and normal samples were constructed using 100ng genomic DNA input and following the protocol as described by Fisher et al.,3 with the following adapter modification: Illumina paired end adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adapter. In-solution hybrid selection was performed using the Illumina Rapid Capture Exome enrichment kit with 38Mb target territory (29Mb baited). The targeted region includes 98.3% of the intervals in the Refseq exome database. Dual-indexed libraries were pooled into groups of up to 96 samples prior to hybridization.
    [Show full text]
  • Catalytically Active MAP KAP Kinase 2 Structures in Complex with Staurosporine and ADP Reveal Differences with the Autoinhibited Enzyme
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Structure, Vol. 11, 627–636, June, 2003, 2003 Elsevier Science Ltd. All rights reserved. DOI 10.1016/S0969-2126(03)00092-3 Catalytically Active MAP KAP Kinase 2 Structures in Complex with Staurosporine and ADP Reveal Differences with the Autoinhibited Enzyme Kathryn W. Underwood,1,* Kevin D. Parris,1,* Mice engineered to be homozygously deficient in MK2 Elizabeth Federico, Lidia Mosyak, show a reduction in TNF-␣, interferon-␥, IL-1␤, and IL-6 Robert M. Czerwinski, Tania Shane, production and an increased rate of survival upon chal- Meggin Taylor, Kristine Svenson, Yan Liu, lenge with LPS, suggesting that this enzyme is a key Chu-Lai Hsiao, Scott Wolfrom, Michelle Maguire, component in the inflammatory process and a potential Karl Malakian, Jean-Baptiste Telliez, target for anti-inflammatory therapy (Kotlyarov et al., Lih-Ling Lin, Ronald W. Kriz, Jasbir Seehra, 1999). Activation of MK2 results in the production of William S. Somers, and Mark L. Stahl cytokines by regulating the translation and or stability Department of Biological Chemistry of the encoding mRNAs through the AU-rich elements Wyeth Research of the 3Ј-untranslated regions of the gene (Neininger et 87 Cambridge Park Drive al., 2002). MK2 also phosphorylates the transcription Cambridge, Massachusetts 02140 factor CREB, as well as leukocyte-specific protein-1 and heat shock protein 25/27, which are involved in the regu- lation of actin polymerization (Tan et al., 1996; Lavoie Summary et al., 1993; Stokoe et al., 1992b; Ben-Levy et al., 1995) and cell migration (Hedges et al., 1999; Kotlyarov et al., MAP KAP kinase 2 (MK2), a Ser/Thr kinase, plays a 2002).
    [Show full text]
  • Mapkapk5)(13H5
    • Order [email protected] • TechnicalOrder [email protected]@biovendor.com • TelTechnical [email protected] • FaxTel +82-2-6933-6780800-404-7807 • WebFax 828-670-7809http://www.abfrontier.com • Web www.biovendor.com MONOCLONAL ANTIBODY Anti-PRAK (MAPKAPK5)(13H5) Catalog No. LF-MA0195 Background : PRAK is a 471 amino acid Positive control : A431 cell lysate protein with 20-30% sequence identity to the known MAP kinase-regulated protein kinases Storage : Store for 1 year at –20 ℃ from date RSK1/2/3, MNK1/2 and MAPKAPK2/3. of shipment The p38 mitogen-activated protein kinase (MAPK) pathway plays an important role in Species cross reactivity cellular responses to inflammatory stimuli and environmental stress. There are at least six protein kinases that can be regulated by p38 α Human Mouse Rat and/or p38 β. These downstream kinases of p38s + + + include MAPK-activated protein kinase 2 (MAPKAPK2 or MK2), MAPKAPK3, MAPK- M.W.(kDa) 1 2 3 4 interacting kinase 1 (MNK1), MNK2, p38- activated/regulated protein kinase (PRAK or 175 MAPKAPK5), and mitogen- and stress-activated 83 protein kinase (MSK). PRAK can be activated in response to cellular stress and proinflammatory 62 cytokines. T182 within the activation loop of 47.5 PRAK has been determined to be the regulatory phosphorylation site. PRAK has been reoprted to 32.5 be essential for ras-induced senescence and tumor suppression. PRAK mediates senescence 25 upon activation by p38 in response to oncogenic ras. Immunoblot Analysis of cell lysates Lane 1 : A431 cell lysate Immunogen : Recombinant human protein E.coli Lane 2 : 293T cell lysate purified from (His-PRAK) Lane 3 : NCI-H460 cell lysate Lane 4 : WI-38 Host : Mouse : Clone number 13H5 Applications : ELISA : Isotype IgG1, k Western blotting (1: 5,000 ~10,000) Size : 100 ㎕ Compositon : Hepes with 0.15M NaCl, Background Reference : 0.01% BSA, 0.03% sodium azide, and 50% 1) Sun P.
    [Show full text]
  • Dema and Faust Et Al., Suppl. Material 2020.02.03
    Supplementary Materials Cyclin-dependent kinase 18 controls trafficking of aquaporin-2 and its abundance through ubiquitin ligase STUB1, which functions as an AKAP Dema Alessandro1,2¶, Dörte Faust1¶, Katina Lazarow3, Marc Wippich3, Martin Neuenschwander3, Kerstin Zühlke1, Andrea Geelhaar1, Tamara Pallien1, Eileen Hallscheidt1, Jenny Eichhorst3, Burkhard Wiesner3, Hana Černecká1, Oliver Popp1, Philipp Mertins1, Gunnar Dittmar1, Jens Peter von Kries3, Enno Klussmann1,4* ¶These authors contributed equally to this work 1Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Robert- Rössle-Strasse 10, 13125 Berlin, Germany 2current address: University of California, San Francisco, 513 Parnassus Avenue, CA 94122 USA 3Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Strasse 10, 13125 Berlin, Germany 4DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Oudenarder Strasse 16, 13347 Berlin, Germany *Corresponding author Enno Klussmann Max Delbrück Center for Molecular Medicine Berlin in the Helmholtz Association (MDC) Robert-Rössle-Str. 10, 13125 Berlin Germany Tel. +49-30-9406 2596 FAX +49-30-9406 2593 E-mail: [email protected] 1 Content 1. CELL-BASED SCREENING BY AUTOMATED IMMUNOFLUORESCENCE MICROSCOPY 3 1.1 Screening plates 3 1.2 Image analysis using CellProfiler 17 1.4 Identification of siRNA affecting cell viability 18 1.7 Hits 18 2. SUPPLEMENTARY TABLE S4, FIGURES S2-S4 20 2 1. Cell-based screening by automated immunofluorescence microscopy 1.1 Screening plates Table S1. Genes targeted with the Mouse Protein Kinases siRNA sub-library. Genes are sorted by plate and well. Accessions refer to National Center for Biotechnology Information (NCBI, BLA) entries. The siRNAs were arranged on three 384-well microtitre platres.
    [Show full text]
  • Gene List HTG Edgeseq Oncology Biomarker Panel
    Gene List HTG EdgeSeq Oncology Biomarker Panel For Research Use Only. Not for use in diagnostic procedures. A2M ADRA2B APH1B BAG1 BRCA2 CARM1 CCNH CDC25A CHI3L1 COX7B CXCL16 DESI1 ABCA2 ADRA2C APOC2 BAG2 BRIP1 CASP1 CCNO CDC25B CHI3L2 CP CXCL2 DFFA ABCA3 AFF1 APOC4 BAG3 BTC CASP10 CCNT1 CDC25C CHMP4B CPT1A CXCL3 DHCR24 ABCA4 AGER APOL3 BAG4 BTG1 CASP12 CCR1 CDC34 CHPT1 CPT1B CXCL5 DHH ABCA5 AGFG1 APP BAG5 BTG2 CASP14 CCR10 CDC42 CHRNA1 CPT1C CXCL6 DHX58 ABCA9 AGGF1 APPBP2 BAI1 BTG3 CASP2 CCR2 CDC42BPA CHRNB1 CPT2 CXCL8 DIABLO ABCB11 AGT AQP1 BAIAP3 BTK CASP3 CCR3 CDC6 CHSY1 CRADD CXCL9 DIAPH3 ABCB4 AHNAK AQP2 BAK1 BTRC CASP4 CCR4 CDC7 CHUK CREB1 CXCR1 DICER1 ABCB5 AHNAK2 AQP4 BAMBI BUB1 CASP5 CCR5 CDCA7 CIC CREB3L1 CXCR2 DISP1 ABCB6 AHR AQP7 BAP1 BUB1B CASP6 CCR6 CDH1 CIDEA CREB3L3 CXCR3 DISP2 ABCC1 AHRR AQP9 BATF C17orf53 CASP7 CCR7 CDH13 CIDEB CREB3L4 CXCR4 DKC1 ABCC10 AICDA AR BAX C19orf40 CASP8 CCR8 CDH15 CIRBP CREB5 CXCR5 DKK1 ABCC11 AIFM1 ARAF BBC3 C1orf106 CASP8AP2 CCR9 CDH2 CITED2 CREBBP CXCR6 DKK2 ABCC12 AIMP2 AREG BBS4 C1orf159 CASP9 CCRL2 CDH3 CKB CRK CXXC4 DKK3 ABCC2 AK1 ARHGAP44 BCAR1 C1orf86 CAV1 CCS CDH5 CKLF CRLF2 CXXC5 DKK4 ABCC3 AK2 ARHGEF16 BCAT1 C1QA CAV2 CCT2 CDK1 CKMT1A CRLS1 CYBA DLC1 ABCC4 AK3 ARID1A BCCIP C1S CBL CCT3 CDK16 CKMT2 CRP CYBB DLGAP5 ABCC5 AKAP1 ARID1B BCL10 C3 CBLC CCT4 CDK2 CKS1B CRTAC1 CYCS DLK1 ABCC6 AKR1B1 ARID2 BCL2 C3AR1 CBX3 CCT5 CDK4 CKS2 CRTC2 CYLD DLL1 ABCD1 AKR1C3 ARMC1 BCL2A1 C5 CBX5 CCT6A CDK5 CLCA2 CRY1 CYP19A1 DLL3 ABCD3 AKT1 ARNT BCL2L1 C5AR1 CCBL2 CCT6B CDK5R1 CLCF1 CRYAA CYP1A1 DLL4
    [Show full text]
  • Genome-Wide Screening Identifies Prognostic Long Noncoding Rnas in Hepatocellular Carcinoma
    Hindawi BioMed Research International Volume 2021, Article ID 6640652, 16 pages https://doi.org/10.1155/2021/6640652 Research Article Genome-Wide Screening Identifies Prognostic Long Noncoding RNAs in Hepatocellular Carcinoma Yujie Feng, Xiao Hu, Kai Ma, Bingyuan Zhang , and Chuandong Sun Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province 266003, China Correspondence should be addressed to Bingyuan Zhang; [email protected] and Chuandong Sun; [email protected] Received 19 October 2020; Revised 18 April 2021; Accepted 23 April 2021; Published 21 May 2021 Academic Editor: Min Tang Copyright © 2021 Yujie Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hepatocellular carcinoma (HCC) is a common malignancy with a poor prognosis. Therefore, there is an urgent call for the investigation of novel biomarkers in HCC. In the present study, we identified 6 upregulated lncRNAs in HCC, including LINC01134, RHPN1-AS1, NRAV, CMB9-22P13.1, MKLN1-AS, and MAPKAPK5-AS1. Higher expression of these lncRNAs was correlated to a more advanced cancer stage and a poorer prognosis in HCC patients. Enrichment analysis revealed that these lncRNAs played a crucial role in HCC progression, possibly through a series of cancer-related biological processes, such as cell cycle, DNA replication, histone acetyltransferase complex, fatty acid oxidation, and lipid modification. Moreover, competing endogenous RNA (ceRNA) network analysis revealed that these lncRNAs could bind to certain miRNAs to promote HCC progression. Loss-of-function assays indicated that silencing of RHPN1-AS1 significantly suppressed HCC proliferation and migration.
    [Show full text]